Literature DB >> 35177227

Utilisation of goals of care discussions and palliative care prior to image-guided procedures near the end of life.

H D Rockwell1, S A Beeson1, E J Keller2, S M Harman3, I G Newton4, N Kothary5.   

Abstract

AIM: To characterise image-guided procedures performed near the end of life and the use of goals of care discussions (GOC) and palliative care consultation (PCC) prior to these procedures.
MATERIALS AND METHODS: Retrospective chart review of 3,714 consecutive inpatient procedures performed for 2,351 patients and 8,206 outpatient procedures performed for 5,225 patients within a suburban medical system. Data were collected on demographics, procedures performed, mortality, and use of GOC or PCC prior to the procedures. Procedures near the end of life were classified as emergent, elective, or palliative. Logistic regression was used to assess for demographic disparities in care.
RESULTS: Nine percent of inpatients died within 30 days of their procedure, 57% of which were within the same hospitalisation. Of these patients, 59% had a documented GOC and 35% had a PCC. Similarly, 7% of outpatients died within 6 months of their procedure. A minority of these patients had a documented GOC (37%) or PCC (13%). There were few statistically significant demographic disparities in this care and the associated odds ratios were small.
CONCLUSION: A wide array of image-guided procedures is performed near the end of life. GOC and PCC are underutilised prior to these procedures. Few demographic disparities exist in this care.
Copyright © 2022 The Royal College of Radiologists. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35177227     DOI: 10.1016/j.crad.2022.01.050

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  1 in total

Review 1.  Suspending Do Not Resuscitate/Do Not Intubate Orders for Image-Guided Procedures.

Authors:  Eric Cyphers; Sara Silberstein; Eric J Keller
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.